Catalog No. |
TD-HY028026 |
Species reactivity |
Human |
Applications |
Research Grade Biosimilar |
Host species |
Humanized |
Isotype |
IgG2-kappa |
Expression system |
Mammalian Cells |
Clonality |
Monoclonal |
Target |
CCP, PDN-21, CALCA, Calcitonin carboxyl-terminal peptide, Calcitonin, CALC1, Calcitonin gene-related peptide II, CALCB, Calcitonin gene-related peptide 2, Beta-CGRP, CALC2, CGRP-II, Beta-type CGRP |
Endotoxin level |
Please contact the lab for this information. |
Purity |
>95% purity as determined by SDS-PAGE. |
Purification |
Protein A/G, purified from cell culture supernatant. |
Accession |
P01258 & P10092 |
Form |
Liquid |
Storage buffer |
0.01M PBS,pH7.4. |
Stability and Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
Alternate Names |
LBR-101,PF-04427429,RI-307,RN-307,TEV-48125,fremanezumab-vfrm,CAS:1655501-53-3 |
Background |
Fremanezumab (TEV-48125) is a humanized IgG2a monoclonal antibody that selectively and potently binds to calcitonin gene-related peptide (CGRP). CGRP is a 37-amino acid neuropeptide involved in central and peripheral pathophysiological events of migraine. Fremanezumab has the potential for chronic migraine research. |
Note |
For research use only. Not for use in clinical or therapeutic applications. |